Stereotactic Body Radiotherapy (SBRT) for liver metastasis - clinical outcomes from the international multi-institutional RSSearch® Patient Registry

• Published in: Radiation oncology (London, England) England), 2018-02, Vol.13 (1), p.26-26, Article 26
• Main Authors: Mahadevan, Anand, Blanck, Oliver, Lanciano, Rachelle, Peddada, Anuj, Sundararaman, Srinath, D'Ambrosio, David, Sharma, Sanjeev, Perry, David, Kolker, James, Davis, Joanne
• Format: Article
• Language: English
• Subjects: Care and treatment; Diagnosis; Liver metastasis; Metastasis; Radiotherapy; RSSearch registry; SBRT
• ISSN: 1748-717X; 1748-717X
• DOI: 10.1186/s13014-018-0969-2

Stereotactic body radiotherapy (SBRT) is an emerging treatment option for liver metastases in patients unsuitable for surgery. We investigated factors associated with clinical outcomes for liver metastases treated with SBRT from a multi-center, international patient registry. Patients with liver metastases treated with SBRT were identified in the RSSearch® Patient Registry. Patient, tumor and treatment characteristics associated with treatment outcomes were assessed. Dose fractionations were normalized to BED . Overall survival (OS) and local control (LC) were evaluated using Kaplan Meier analysis and log-rank test. The study included 427 patients with 568 liver metastases from 25 academic and community-based centers. Median age was 67 years (31-91 years). Colorectal adenocarcinoma (CRC) was the most common primary cancer. 73% of patients received prior chemotherapy. Median tumor volume was 40 cm (1.6-877 cm ), median SBRT dose was 45 Gy (12-60 Gy) delivered in a median of 3 fractions [1-5]. At a median follow-up of 14 months (1-91 months) the median overall survival (OS) was 22 months. Median OS was greater for patients with CRC (27 mo), breast (21 mo) and gynecological (25 mo) metastases compared to lung (10 mo), other gastro-intestinal (GI) (18 mo) and pancreatic (6 mo) primaries (p